SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Acquisition and Licensing agreement

26 Sep 2013 07:00

RNS Number : 9175O
Porvair PLC
26 September 2013
Β 

ο»Ώ

FOR IMMEDIATE RELEASE 26 September 2013

Β 

Β 

Β 

Licensing agreement with Thermo Fisher Scientific

Β and

Acquisition of Thomas Cain Inc

Porvair plc ("Porvair"), the specialist filtration and environmental technology group today, today announces two agreements to advance its interests in the life science and environmental laboratory markets.

A technology licensing agreement has been struck with Thermo Electron Manufacturing Ltd, a division of Thermo Fisher Scientific ("Thermo"), a global leader in scientific and laboratory supplies. Under this agreement, Porvair and Thermo will commercialise an exclusive range of life science sample preparation filters. Porvair has licensed its filter technology and will manufacture the products. Thermo will undertake sales and marketing of the filters worldwide.

Β 

In an unrelated agreement, Porvair has acquired the business and assets of Thomas Cain Inc, a manufacturer of environmental laboratory equipment and consumables. This small acquisition will add a complementary range of block digestion instruments and consumables to Seal's water quality analysis products. The business will be integrated into Seal Analytical's operation in Wisconsin, USA.

Β 

Ben Stocks, Group Chief Executive, commented:

"As part of Porvair's focus on new product development, we have been working for several years with Thermo to develop a range of laboratory sample preparation products, which we are excited to see move into the commercial phase. Porvair has received a technology transfer fee and, in addition, will generate manufacturing margins and royalties on future revenues.

Β 

"I am pleased to welcome the staff of Thomas Cain into the Porvair Group. Their high quality product range is highly complementary to that offered by Seal Analytical and will fit well with sales and marketing programmes already underway."

Β 

Β 

For further information, please contact:

Β 

Porvair plc

01553 765 500

Ben Stocks, Chief Executive

Chris Tyler, Group Finance Director

Buchanan

0207 466 5000

Charles Ryland / Helen Greenwood / Clare Akhurst

Β 

Notes to Editors

Porvair is a group of specialist filtration and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. Its principal markets are aviation, energy and industrial process, environmental laboratories and non-ferrous metals.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCBUGDCGUDBGXU
Date   Source Headline
27th Mar 20257:00 amRNSGrant of SAYE Options
18th Mar 20257:40 amRNSHolding(s) in Company
17th Mar 20253:30 pmRNSHolding(s) in Company
14th Mar 20257:00 amRNSNotice of Annual General Meeting; Accounts posting
4th Mar 20253:00 pmRNSHolding(s) in Company
12th Feb 20252:30 pmRNSDirector/PDMR Shareholding
10th Feb 20257:00 amRNSFull Year Results
12th Dec 20241:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSTrading update and notice of results
2nd Dec 20243:01 pmRNSTotal Voting Rights
2nd Dec 20243:00 pmRNSDirector/PDMR Shareholding
25th Nov 20244:37 pmRNSShareholder Communications
28th Oct 20247:00 amRNSBoard appointment
1st Oct 20247:00 amRNSTotal Voting Rights
23rd Sep 20247:00 amRNSAppointment of Chief Executive Officer
2nd Sep 20245:15 pmRNSDirector/PDMR Shareholding
2nd Sep 20245:00 pmRNSTotal Voting Rights
31st Jul 202410:45 amRNSTotal Voting Rights
31st Jul 202410:30 amRNSBlock listing Interim Review
29th Jul 20246:15 pmRNSDirector/PDMR Shareholding
1st Jul 20247:00 amRNSInterim Results
27th Jun 20242:26 pmRNSDirector/PDMR Shareholding
23rd Apr 20241:38 pmRNSDirector/PDMR Shareholding
16th Apr 20242:56 pmRNSAGM Results Announcement
16th Apr 20247:00 amRNSAGM Trading Update & Board Update
3rd Apr 20247:00 amRNSDirector resignation
12th Mar 20247:00 amRNSDirector declaration
29th Feb 20247:00 amRNSTotal Voting Rights
8th Feb 20244:41 pmRNSHolding(s) in Company
8th Feb 20244:27 pmRNSDirector/PDMR Shareholding
5th Feb 20247:00 amRNSResults for the year ended 30 November 2023
1st Feb 20247:00 amRNSBlock listing Interim Review
19th Dec 202310:25 amRNSHolding(s) in Company
5th Dec 20237:00 amRNSTrading Update & Acquisition
4th Dec 202312:00 pmRNSHolding(s) in Company
25th Sep 202310:00 amRNSDirector/PDMR Shareholding
12th Sep 20237:00 amRNSNine Month Trading Update
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
17th Jul 20237:00 amRNSAcquisition completion
7th Jul 20234:00 pmRNSBlock Listing Application
3rd Jul 20237:00 amRNSInterim Results
26th Jun 20237:00 amRNSBoard Change
21st Jun 20234:22 pmRNSHolding(s) in Company
21st Jun 20237:00 amRNSDirector/PDMR Shareholding
15th Jun 20237:00 amRNSBlock listing Interim Review
4th May 20237:00 amRNSAcquisitions
18th Apr 202312:51 pmRNSAGM resolutions
18th Apr 20237:00 amRNSAGM Trading Update
31st Mar 20234:00 pmRNSTotal Voting Rights
22nd Mar 20233:03 pmRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.